Translational Development Acquisition (TDACW) Invested Capital (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Invested Capital for 4 consecutive years, with -$6.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital changed N/A year-over-year to -$6.6 million; the trailing twelve-month figure through Jun 2026 stood at -$6.6 million (changed N/A YoY), and the FY2025 full-year result was -$6.3 million, down 13.3% from the prior year.
• Invested Capital eased to -$6.6 million in Q2 2026 per TDACW's latest filing, from -$6.3 million in the prior quarter.
• Across five years, Invested Capital topped out at -$160158.0 in Q4 2023 and bottomed at -$6.6 million in Q2 2026.
• Historically, Invested Capital has averaged -$5.2 million across 4 years, with a median of -$6.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Invested Capital tumbled 3395.03% in 2024, then dropped 13.3% in 2025.
• Over 4 years, Invested Capital stood at -$160158.0 in 2023, then sank by 3395.03% to -$5.6 million in 2024, then declined by 13.3% to -$6.3 million in 2025, then fell by 3.82% to -$6.6 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered -$6.6 million, -$6.3 million, and -$6.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.